Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lexaria Bioscience Corp (LEXX)

Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,802
  • Shares Outstanding, K 15,819
  • Annual Sales, $ 230 K
  • Annual Income, $ -6,660 K
  • EBIT $ -5 M
  • EBITDA $ -4 M
  • 60-Month Beta 1.02
  • Price/Sales 56.11
  • Price/Cash Flow N/A
  • Price/Book 2.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 08/31/24
See More
  • Average Estimate -0.11
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.12
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.95 +8.74%
on 11/15/24
2.87 -26.12%
on 10/22/24
-0.63 (-22.89%)
since 10/21/24
3-Month
1.95 +8.74%
on 11/15/24
4.38 -51.59%
on 08/30/24
-1.17 (-35.55%)
since 08/21/24
52-Week
1.20 +76.70%
on 01/04/24
6.85 -69.05%
on 03/11/24
+0.86 (+68.29%)
since 11/21/23

Most Recent Stories

More News
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study

DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in both body weight-loss, by 11.53% and 10.65% respectively,...

LEXXW : 0.7484 (+21.43%)
LEXX : 2.12 (-3.62%)
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups

LEXXW : 0.7484 (+21.43%)
LEXX : 2.12 (-3.62%)
Lexaria (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, looks to offer a better alternative to diabetes management and treatment through its patented DehydraTECH(TM) technology....

LEXXW : 0.7484 (+21.43%)
LEXX : 2.12 (-3.62%)
Lexaria (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Collaboration

Lexaria (NASDAQ: LEXX), a global innovator in drug delivery platforms, has, since 2016, worked on the development of its patented DehydraTECH(TM) technology. It has repeatedly demonstrated the ability...

LEXX : 2.12 (-3.62%)
Lexaria (NASDAQ: LEXX) Demonstrates DehydraTECH(TM)-Liraglutide Performance with GLP-1 Diabetes Animal Study

Lexaria (NASDAQ: LEXX), a global innovator in drug delivery platforms, is reporting on its eight-week body weight results from its WEIGHT-A24-1 ongoing animal study. This study explores Lexaria’s patented...

LEXX : 2.12 (-3.62%)
Lexaria (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently released its fiscal report for the third quarter of the 2024 financial year (“Q3, 2024”). “Of note was growth in cash and marketable securities from...

LEXXW : 0.7484 (+21.43%)
LEXX : 2.12 (-3.62%)
Lexaria Bioscience (NASDAQ: LEXX) Shares Letter from Outgoing CEO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, provided a strategic letter from outgoing CEO Chris Bunka updating all stakeholders. In the strategic update, Bunka...

LEXX : 2.12 (-3.62%)
LEXXW : 0.7484 (+21.43%)
Lexaria (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of Richard Christopher as the new CEO, effective August 31, 2024. Mr. Christopher...

LEXX : 2.12 (-3.62%)
LEXXW : 0.7484 (+21.43%)
Lexaria (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) Liraglutide

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its 4-week and 8-week blood glucose results from its WEIGHT-A24-1 animal study (the “study”). This study...

LEXX : 2.12 (-3.62%)
Lexaria (NASDAQ: LEXX) Announces Agreement to Evaluate DehydraTECH(TM) in Pre-Clinical Setting

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has entered into a Materials Transfer Agreement with a pharmaceutical company. Under the terms of the agreement,...

LEXX : 2.12 (-3.62%)

Business Summary

Lexaria Bioscience Corp. provides drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules....

See More

Key Turning Points

3rd Resistance Point 2.39
2nd Resistance Point 2.34
1st Resistance Point 2.27
Last Price 2.12
1st Support Level 2.14
2nd Support Level 2.09
3rd Support Level 2.02

See More

52-Week High 6.85
Fibonacci 61.8% 4.69
Fibonacci 50% 4.03
Fibonacci 38.2% 3.36
Last Price 2.12
52-Week Low 1.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar